Wednesday, March 9:

13:00 Welcome

13:15 - 15:20 Session I
Pathophysiology - new aspects:
Chairs: M Edinger
13:40 - 14:05 Sting/IFN signaling and microbiota: H Poeck, Regensburg
14:05 - 14:30 Role of neutrophils: R Zeiser, Freiburg
14:30 - 14:55 Tissue tolerance: P Reddy, Ann Arbor
14:55 - 15:20 IL22 and intestinal stem cells: AM Hanash, New York, virtual

15:20 - 15:45 Break

15:45 - 17:25 Session II
Biomarkers and Pathophysiology II:
Chairs: A Beilhack
15:45 - 16:10 Update on MAGIC: J Levine, New York
16:10 - 16:35 Tissue T regs: M Feuerer, LIT Regensburg (SFB)
16:35 - 17:00 T Reg repertoire: C Koenecke, Hannover
17:00 - 17:25 Interplay between endothelial damage, atherosclerosis and GvHD: A Zerneck, Würzburg

17:25 - 18:15 HJ Kolb Award and lecture 2022

18:45 - 20:15 Evening discussion
Thursday, March 10:

09:00 – 10:40 Session III
Immune Cells and immunoreconstitution
Chairs: P. Hoffmann
09:00 - 09:25 CD4 reconstitution and outcome: C. Lindemans, Utrecht
09:25 - 09:50 Enhancing thymic recovery: E Velardi, Rome
09:50 - 10:15 Tumor specific T cells in myeloma and HD: L Hansmann, Berlin
10:15 - 10:40 Peripheral antigen display and autoimmunity in GVHD: R Chakraverty, London

10:40 - 11:00 Break

11:00 - 12:15 Session IV
IgA
Chair: A Gessner
11:00 - 11:25 Intestinal IgA. Microbiota and immunoregulation: O Pabst, Aachen
11:25 - 11:50 IgA in chronic GvHD: T Winkler, Erlangen
11:50 - 12:15 Intestinal IgA pos plasma cells and GvH/GVL: E Holler, Regensburg

12:15 - 13:30 Break

13:30 - 14:20 Session V
New Treatment Options in acute GvHD
Chair: R Zeiser
13:55 - 14:20 RIPK1 Inhibition and acute GvHD: JLM Ferrara, New York

14:20 - 15:10 Session VI
New Treatment Options in cGvHD
Chair: D Wolff
14:20 - 14:45 T Regs in chronic GvHD: M Edinger, Regensburg
14:45 - 15:10 Drug targetable biomarkers of chronic GvHD: S Paczesny, Indianapolis
15:10 – 15:35 Wnt signaling in cGvHD: J Distler, Erlangen

15:35 – 16:00 Break

16:00 – 16:40 Keynote lecture
Chairs: S Thomas, HJ Kolb
The role of CAR T cells in the setting of allogeneic SCT: M v d Brink, New York

16:40 – 17:00 Break

17:00 - 18:15: GvL I
Chairs: A Mackensen
17:00 - 17:25 Novel hemibodies for personalized GvL Therapy: G Stuhler
17:25 - 17:50 DP specific strategies: K Fleischhauer, Essen
17:50 - 18:15 Regulation of class II to prevent relapse: H Reimann, Erlangen
Friday, March 11:

09:00 – 10:40 GvL II
Chairs: H Einsele
09:00 - 09:25 Immune signature drives leukemia escape after aHSCT: L. Vago, Milano
09:25 - 09:50 Harnessing immune exhaustion for adoptive T cell therapy of acute myeloid leukemia: Beatrice Cianciotti, Milano
09:50 - 10:15 mutNPM1–specific TCR in AML: Marieke Griffioen, Leiden
10:15 - 10:40 T Cell metabolism and immune escape: D Mougiaakos

10:40 – 11:00 Coffee Break

11:00 – 12:35 GvL III
Chairs: P Beckhove
11:00 - 11:25 Genome edited allo-CART: G Lucchini, London
11:25 - 11:50 Novel targets for CAR T cells in myeloma and AML: M Hudecek, Würzburg
11:50 - 12:15 CART and memory T stem cells: L Gattinoni, Regensburg
12:15 - 12:40 CAR T cell resistance: L Rasche, Würzburg

12:40 – 13:00 Closure and farewell